The company wants to make Texas "the home of self-driving trucks." PRNewsfoto/Kodiak Robotics

The Interstate 45 freight corridor between Houston and Dallas now serves as a testing ground for self-driving cargo trucks.

Silicon Valley startup Kodiak Robotics Inc. recently began sending its autonomous 18-wheel trucks on trips between Texas' two largest metro areas, co-founder and CEO Don Burnette says. The trucks are carrying paid cargo, but Kodiak won't identify the customer or customers. The company also won't say how many trips the trucks are making each day.

The Texas initiative represents Kodiak's first foray into commercial deliveries. Wired.com notes that pretty much every player in the autonomous truck sector has conducted tests in Texas or is carrying commercial loads in the Lone Star State, which boasts more than 2,300 miles of interstate highways.

For its part, Kodiak aims to make Texas "the home of self-driving trucks."

According to a 2016 report from the Texas Department of Transportation, nearly half of all truck freight in Texas goes through the I-45 corridor's 11 counties. In some spots, trucks make up more than one-fourth of the traffic in the corridor, which runs 276 miles from Galveston to where I-45 intersects with Interstate 20 in Dallas County, the TxDOT report says.

"The importance of the I‐45 freight corridor to the movement of goods extends beyond Texas because much of the freight originating or passing through the corridor is destined to other domestic and international markets," the report says.

For now, Burnette says, two people are aboard each Kodiak truck traveling between Houston and Dallas — a safety driver and a safety engineer.

"Dallas will be our home base for testing and operations for the foreseeable future," Burnette says. "Kodiak plans to continue refining and testing its trucks until the last truck-involved accident happens on public roads."

Kodiak's Dallas office, which opened in March, employs eight people. The company plans to relocate soon to new office space in the Dallas suburb of Lancaster, Burnette says.

At this time, Kodiak doesn't plan to hire any workers in Houston, he says.

From its base in the Dallas area, Kodiak envisions expanding its service to routes throughout Texas, but it's focusing solely on the Houston-to-Dallas route for the time being, Burnette says.

Kodiak picked Texas for its truck tests, in part, because of the "warm welcome" extended by Gov. Greg Abbott, TxDOT, the Texas Department of Public Safety, the Texas A&M Transportation Institute, and other segments of the public sector, he says.

In addition, Burnette says, Kodiak chose Texas "because of its great people, freight-rich economy, reasonable regulatory structure, and robust infrastructure."

In 2017, Texas enacted laws enabling driverless vehicles, including long-haul trucks, to operate on the state's roads.

"Texas is a leader in the testing and implementation of connected and automated vehicles, and Kodiak's willingness to partner with academia and public agencies to ensure safe deployment of new technology will add significant value to our transportation system," Christopher Poe, assistant director of the Texas A&M Transportation Institute, says in a release.

Burnette, co-founder of Otto Trucking LLC, a self-driving truck startup purchased in 2016 by Uber Technologies Inc., and fellow entrepreneur Paz Eshel established Kodiak in 2018 to "redefine" long-haul trucking through self-driving technology.

Kodiak says its autonomous technology is designed to ease pressures facing the trucking industry, including a shortage of drivers and high turnover among drivers, while improving highway safety, fostering business efficiency, reducing traffic congestion, and cutting down on harmful emissions.

"Long-haul trucking is primed for autonomous technology," Kodiak says in a post on Medium. "Highway driving is more structured and predictable than urban driving. This means there are fewer decisions for drivers to make and [it's] a better fit for autonomous vehicles."

"As hard as it is to navigate city streets, autonomous vehicles are much closer to being able to drive on more structured interstate highways, which have no jaywalking pedestrians, no aggressive cyclists, and no runaway pets," Kodiak adds. "That's why we've focused on building technology specifically for long-haul trucks driving on highway routes, often referred to as the 'middle mile.'"

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

Houston billionaire Tilman Fertitta nominated as ambassador to Italy

foreign affairs

Houston billionaire and Rockets owner Tilman Fertitta has been nominated to serve as the United States ambassador to Italy, according to U.S. President-elect Donald Trump.

On Saturday, Trump sent the following statement via Truth Social Post:

"I am pleased to announce that Tilman J. Fertitta has been nominated to serve as the United States Ambassador to Italy. Tilman is an accomplished businessman, who has founded and built one of our Country's premier entertainment and real estate companies, employing approximately 50,000 Americans. Tilman has a long history of giving back to the community through numerous philanthropic initiatives, which include children's charities, Law Enforcement, and the medical community. Additionally, Tilman is the longest serving Chairman of the Board of Regents for the University of Houston. He also owns the Houston Rockets Basketball Team. Congratulations to Tilman, and his remarkable family!"

Fertitta, 67, also is the chairman, CEO, and president of Landry's Inc. and the chairman of the University of Houston's board of regents.

"It is an honor to be nominated to serve my country as ambassador to Italy and I look forward to the process ahead. Italy is such an extraordinary country with its wonderful people, culture, and history and its strategic importance to The United States of America," Fertitta said.

---

Read the full story on CultureMap's news partner, ABC13.com.

Houston biotech biz to merge with public co., set local HQ

big deal

Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters.

Tvardi is a clinical-stage biopharmaceutical company that focuses on the development of novel, oral, and small molecule therapies that target STAT3 to treat fibrosis-driven diseases. Tvardi will merge with a wholly owned subsidiary of Cara.

Once complete, the pre-merger Cara Therapeutics stockholders are expected to own approximately 17 percent of the combined company and pre-merger Tvardi Therapeutics investors are expected to own 83 percent of the combined company. Prior to adjustment from the issuance of the shares in the recently completed Tvardi financing and assuming Cara, which went public in 2014, has net cash at closing of between $22.9 million and $23.1 million with the percentage of the combined company that pre-merger Cara stockholders and pre-merger Tvardi stockholders will own upon the closing of the merger, which is subject to further adjustment if Cara’s net cash balance falls outside of the range.

“As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs,” Imran Alibhai, CEO of Tvardi Therapeutics, says in a news release.

Also, Tvardi has completed an approximately $28 million private financing from a syndicate of new and existing institutional investors. With the cash from both companies at closing and the proceeds of this financing, the post-merger company plans to have cash to fund its operating expenses and capital expenditure requirements into the second half of 2026.

“I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases,” Alibhai continues.

In 2021, Tvardi emerged from stealth and closed a $74 million series B funding round led by New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.